Literature DB >> 10487549

Intraoperative electron beam radiation therapy for locally recurrent rectal carcinoma.

G H Mannaerts1, H Martijn, M A Crommelin, G N Stultiëns, W Dries, O J van Driel, H J Rutten.   

Abstract

PURPOSE: Treatment results for locally recurrent rectal cancers are poor. This is a result of the fact that surgery is hampered due to the severance of the anatomical planes during the primary procedure and that radiotherapy is limited by normal tissue tolerance, especially after previous irradiation. This paper describes the results of a combined treatment modality in this patient group. METHODS AND MATERIALS: From 1994 to 1998, 37 patients with locally recurrent rectal cancer, but without distant metastatic disease, received a combined treatment consisting of 50.4 Gy preoperative irradiation or, in case of previous radiotherapy, 30 Gy reirradiation or no irradiation, followed by radical surgery and intraoperative electron beam radiotherapy boost.
RESULTS: Fifteen patients received a radical resection (R0), eight a microscopic irradical resection (R1), and 14 a macroscopic irradical resection (R2). The overall 3-year local control (LC), disease-free survival (DFS), and overall survival rates were 60%, 32%, and 58% respectively. Radicality of resection (R0/R1 vs. R2) turned out to be the significant factor for improved survival (p < 0.05), DFS (p = 0.0008), and LC (p = 0.01). Preoperative (re-)irradiation is the other significant factor in survival (p = 0.005) and DFS (p = 0.001) and was almost significant for LC (p = 0.08). After external beam radiation therapy (EBRT) a significantly higher resection rate was obtained (R0/R1 vs. R2 p = 0.001). Symptomatic peripheral local recurrences have a significantly worse prognosis and higher rate of R2-resection (p = 0.0005).
CONCLUSION: Centralization of locally recurrent rectal cancer patients enabled the development of an aggressive multimodality treatment, which in turn led to promising results. Distant failure is still a drawback.

Entities:  

Mesh:

Year:  1999        PMID: 10487549     DOI: 10.1016/s0360-3016(99)00212-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Authors:  Amar U Kishan; Justin C Voog; Jonathan Wiseman; Ryan R Cook; Marek Ancukiewicz; Percy Lee; David P Ryan; Jeffrey W Clark; David L Berger; James C Cusack; Jennifer Y Wo; Theodore S Hong
Journal:  Br J Radiol       Date:  2017-06-14       Impact factor: 3.039

Review 2.  Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer.

Authors:  Rolf Sauer
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

3.  Management of locally advanced primary and recurrent rectal cancer.

Authors:  Johannes H W de Wilt; Maarten Vermaas; Floris T J Ferenschild; Cornelis Verhoef
Journal:  Clin Colon Rectal Surg       Date:  2007-08

4.  Surgical management of locally recurrent rectal cancer.

Authors:  Niamh M Hogan; Myles R Joyce
Journal:  Int J Surg Oncol       Date:  2012-06-03

5.  Combined therapy: surgery and intraoperative HDR brachytherapy for locally advanced and recurrent rectal cancer. Practical experience of Brachytherapy Department in Warsaw.

Authors:  Piotr Gierej; Jakub Radziszewski; Jaroslaw Lyczek; Maria Kawczynska; Anna Kulik
Journal:  J Contemp Brachytherapy       Date:  2009-03-23

6.  Abdominosacral resection for locally recurring rectal cancer.

Authors:  Filiberto Belli; Alessandro Gronchi; Carlo Corbellini; Massimo Milione; Ermanno Leo
Journal:  World J Gastrointest Surg       Date:  2016-12-27

7.  Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.

Authors:  Raphaëla C Dresen; Marleen J Gosens; Hendrik Martijn; Grard A Nieuwenhuijzen; Geert-Jan Creemers; Alette W Daniels-Gooszen; Adriaan J van den Brule; Hetty A van den Berg; Harm J Rutten
Journal:  Ann Surg Oncol       Date:  2008-04-04       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.